Skip to content
TrialScanner

NCT04429191

JSP191 Antibody Conditioning Regimen in MDS/AML Subjects Undergoing Allogenic Hematopoietic Stem Cell Transplantation

Phase 1CompletedJSPRLead

Registry record

Lead sponsor
Jasper Therapeutics, Inc.
Conditions
MYELODYSPLASTIC SYNDROME; MDS; ACUTE MYELOID LEUKEMIA; AML
Primary completion
Jun 13, 2023Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT04429191 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT04429191: JSP191 Antibody Conditioning... | TrialScanner